Zentynel Frontier Investments
Overview
Zentynel Frontier Investments is a Latin American venture capital firm specializing in biotechnology and healthtech sectors. Founded through the convergent vision of Fundación Ciencia & Vida and Venturance Alternative Assets, the firm combines capital, scientific depth, and operational expertise to help founders turn breakthrough science into scalable businesses. With Fund I, Zentynel invested in 17 companies across six countries, catalyzing over US$100 million in co-investments. Fund II, a US$50 million vehicle, focuses on bridging the region's critical capital gap in biotechnology and healthtech, aiming to create impact across human, animal, and environmental health. The firm's investment strategy targets early-stage ventures with global ambition and strong ties to Latin America, focusing on human and animal health, digital health and AI-driven platforms, and agtech, foodtech, and environmental biotech solutions. Typical investments range from US$1–2 million, with 25–30% of the fund reserved for follow-ons. Zentynel is an active investor, working alongside founders with hands-on operational support, international networks, and strategic guidance to accelerate growth and maximize impact. The firm's portfolio includes companies such as HeXemBio, Asclepii, Fecundis, Axenya, ViewMind, Xeptiva, Biomakers, HARMONY, ISA, Microterra, Samay, Autem Medical, Multiplai, and Learning to Sleep. Notably, in June 2022, Zentynel led a $10 million Series A-1 financing round for Autem Therapeutics, a company developing a novel bioelectric oncology treatment platform targeting liver cancer and other solid tumors. This investment underscores Zentynel's commitment to advancing innovative biotech solutions in Latin America. Additionally, in December 2023, Zentynel facilitated an agreement between the Institut Pasteur de Montevideo and Xeptiva Therapeutics, a biotech startup focused on immunotherapies for chronic inflammation in pets. This partnership highlights Zentynel's role in fostering collaborations that drive biotech innovation in the region. Through its strategic investments and partnerships, Zentynel Frontier Investments continues to empower Latin American biotech entrepreneurs, contributing to the growth and global competitiveness of the region's biotech industry.
Get the full list of 54,000+ investors
Zentynel Frontier Investments and every other firm and angel in the database — as one spreadsheet you keep.
$19one-time payment · no subscription- All 54,000+ investors — VC firms, private equity, family offices and angels
- The key person to contact at each one, with their job title
- Their work email address
- Their phone number
- Their LinkedIn profile
- Delivered as a single .xlsx file — download it as many times as you like
Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.
Frequently asked questions about Zentynel Frontier Investments
What sectors does Zentynel Frontier Investments invest in?
Zentynel Frontier Investments invests in HealthTech, FoodTech, Agtech, Biotechnology and Environmental Biotech, and is based in Santiago Metropolitan Region, Chile. Zentynel Frontier Investments is listed as a venture capital in the ConnectSafely investor database.
What stage does Zentynel Frontier Investments invest at?
Zentynel Frontier Investments backs companies at Seed, Early Stage, Series A, Series B and Growth, writing cheques of 1M - 2M.
Which regions does Zentynel Frontier Investments invest in?
Zentynel Frontier Investments invests across Brazil, Mexico, Chile, Argentina, Colombia and Uruguay.
Who are the partners at Zentynel Frontier Investments?
Team members listed for Zentynel Frontier Investments include Pablo Fernandez (General Partner) and Martha Laura (Operational Partner Mexico).
How do I contact Zentynel Frontier Investments?
Zentynel Frontier Investments's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
